This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Oscar H. Del Brutto, MD
Department of Neurology Hospital Luis Vernaza PO Box 3734 Guayaquil, Ecuador

Arch Neurol. 1990;47(12):1278.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—I have read with interest the article by Alarcón et al,¹ as it showed that the length of albendazole therapy for parenchymal brain cysticercosis could be considerably shortened without lessening its efficacy. The authors did not state, however, how the 3-day course of albendazole treatment was chosen. Was it chosen on an empirical basis? If so, a larger number of patients was needed to support their findings.

Albendazole is an imidazole with intense antiparasitic properties that has largely replaced praziquantel as the drug of choice for parenchymal brain cysticercosis.^2-4 The initial length of 30 days of albendazole therapy for neurocysticercosis⁵ was settled according to that previously used for the treatment of human hydatidosis.⁶ When treating patients with cysticercosis, however, two observations suggested that the therapeutic effect of the drug occurred far before the full course of 30 days was completed: first, most patients . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?